School of Medicine
Showing 81-100 of 512 Results
-
Helio Costa
Adjunct Clinical Assistant Professor, Pathology
BioHelio Costa, PhD, is a medical geneticist specializing in oncology, genomics, computational biology, data science, artificial intelligence, and product development. His work focuses on developing new cancer therapies and medical software to improve cancer patient care. He currently serves as Senior Medical Director and Head of Molecular Therapeutics & Drug Development at Natera and is an Adjunct Clinical Assistant Professor in the Department of Pathology at Stanford Medical School.
Dr. Costa’s research spans the entire drug development pipeline, from discovery to FDA-approved therapies. He leads efforts in developing innovative cancer treatments by integrating advanced genomics, computational biology, and AI-driven methodologies. His team focuses on the creation of targeted molecular therapeutics, using large-scale genetic data to identify novel treatment pathways and predict patient responses. In addition to drug discovery, Dr. Costa oversees the clinical trials necessary for validating these therapies, ensuring they meet rigorous standards for safety and efficacy. Furthermore, he manages the product development and commercialization process, guiding new treatments from initial research through to market-ready, FDA-approved cancer therapies.
In addition to his therapeutic work, Dr. Costa has led the development and implementation of genetic diagnostic tests and clinical algorithms used to support therapeutic decisions at Stanford Health Care. His contributions include the creation of DNA and RNA cancer diagnostic tests, as well as algorithms that analyze large-scale laboratory datasets and electronic medical records to predict patient outcomes. As a co-investigator with the NIH Clinical Genome Resource (ClinGen) Consortium, Dr. Costa oversaw developing FDA-recognized medical software used by healthcare providers, researchers, and biotech companies to assess the clinical relevance of genes and mutations.
He is the founding director of the Stanford Clinical Data Science Fellowship, where post-doctoral medical fellows engage in interdisciplinary clinical research and implement real-world health data solutions within Stanford Health Care. Dr. Costa is also an Attending Medical Geneticist for the Molecular Genetic Pathology Laboratory at Stanford Health Care, where he previously served as Assistant Lab Director.
Dr. Costa holds a BS in Genetics from the University of California, Davis, a PhD in Genetics from Stanford University School of Medicine, and completed his ABMGG Clinical Molecular Genetics and Genomics fellowship training at Stanford University School of Medicine. -
Tina Cowan
Professor of Pathology (Clinical) and, by courtesy, of Pediatrics (Genetics)
Current Research and Scholarly Interestsscreening and diagnosis of patients with inborn errors of metabolism, including newborn screening, development of new testing methods and genotype/phenotype correlations.
-
Gerald Crabtree
David Korn, MD, Professor of Pathology and Professor of Developmental Biology
Current Research and Scholarly InterestsChromatin regulation and its roles in human cancer and the development of the nervous system. Engineering new methods for studying and controlling chromatin and epigenetic regulation in living cells.
-
Ronaldo Francisco Jr
Postdoctoral Scholar, Pathology
BioI am a geneticist focused on the application of computational and statistical methods to study genetic mechanisms of disease. My research interests include (i) genomic and precision medicine; (ii) detection and analysis of genetic variants using NGS data (WGS, WES, RNA-Seq); and (iii) transcriptome and allele-specific expression.
-
John W. Day, MD, PhD
Professor of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
Current Research and Scholarly InterestsOur Neuromuscular Division coordinates a comprehensive effort to conquer peripheral nerve and muscle disorders, including the muscular dystrophies, motor neuron disorders, neuromuscular junction abnormalities, and peripheral neuropathies. With patients and families foremost in mind, we have had success defining and combating these diseases, with research focused on identifying genetic causes, developing novel treatment, and maximizing patient function by optimizing current management.
-
Dr. Qiwen Deng
Postdoctoral Scholar, Pathology
BioHow fibroblasts participate in the organ fibrosis and whether targeting fibroblasts is a good strategy to reverse fibrosis is still a mystery. We have identified two important immune checkpoints, CD47 and PD-L1, are highly expressed in fibroblasts and blocking CD47 and PD-L1 reversed lung fibrosis. This is a prove of concept that targeting immune regulatory pathways could be an effective therapeutic approach to treat fibrotic diseases. In addition to identifying novel targets for the treatment of fibrosis, I am also interested in the crosstalk between fibroblasts and innate immune cells in the development of fibrosis. Combined with cutting-edge NGS approaches including single cell sequencing, spatial transcriptomics and high-dimensional CyTOF technique, we have identified several potential targets and characterized immune cells landscape in lung fibrosis. In the long run, I will focus on the validation of these targets. Specifically, I will apply gain- and loss-function approaches to investigate their role in fibrosis in vitro and in vivo.
-
Dylan Dodd
Assistant Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsHarnessing the gut microbiome to treat human disease.
-
Fei Dong
Associate Professor of Pathology
BioDr. Dong is the Associate Director of Molecular Pathology at Stanford Health Care. His clinical interests include the implementation and interpretation of laboratory developed tests in diagnosis and patient care. Previous accomplishments include the development of novel bioinformatics algorithms to infer microsatellite instability and allogeneic contamination from cancer sequencing data. Before arriving at Stanford, Dr. Dong was on faculty at Brigham and Women’s Hospital/Harvard Medical School for nine years, where he established a track record in education and mentorship and was the recipient of both the Anatomic Pathology and Clinical Pathology resident teaching awards. Dr. Dong has served on national/international committees for the Association for Molecular Pathology, the Clinical and Laboratory Standards Institute, and the College of American Pathologists and serves on the editorial boards of multiple academic journals, including the Archives of Pathology and Laboratory Medicine, the Journal of Molecular Diagnostics, and Modern Pathology.
